Genomtec (WAR:GMT) EBIT per Share: zł-0.60 (TTM As of Mar. 2026)


WAR:GMT Genomtec SA WAR:GMT
30 GF Score
Price zł4.80
! 5 Warning Signs
View Full Analysis

What is Genomtec EBIT per Share?

Genomtec WAR:GMT +1.05% 30 EBIT per Share is zł-0.60 as of Mar. 2026. GuruFocus rates WAR:GMT with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Genomtec ranks better than 61.83% on this metric.

Genomtec's EBIT per Share for the three months ended in Mar. 2026 was zł-0.14. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.60.

During the past 3 years, the average EBIT per Share Growth Rate was 17.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genomtec's EBIT per Share or its related term are showing as below:

WAR:GMT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -82.7   Med: 1.7   Max: 18.4
Current: 17.8

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Genomtec was 18.40% per year. The lowest was -82.70% per year. And the median was 1.70% per year.

WAR:GMT's 3-Year EBIT Growth Rate is ranked better than
61.83% of 689 companies
in the Medical Devices & Instruments industry
Industry Median: 9.4 vs WAR:GMT: 17.80

Genomtec's EBIT for the three months ended in Mar. 2026 was zł-2.14 Mil.

Genomtec  (WAR:GMT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genomtec EBIT per Share Related Terms

Genomtec EBIT per Share Historical Data

* Premium members only.

The historical data trend for Genomtec's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomtec EBIT per Share Chart

Genomtec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -0.87 -1.24 -0.71 -0.81 -0.67

Genomtec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.21 -0.16 -0.09 -0.14
WAR:GMT
30GF Score
Genomtec SA WAR:GMT
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomtec EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genomtec's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-10.194/15.180
=-0.67

Genomtec's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.144/15.180
=-0.14

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of zł-0.60 mean?
Genomtec (WAR:GMT) has a EBIT per Share of zł-0.60 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genomtec and its competitors. According to the industry distribution chart, Genomtec ranks #263 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Genomtec's EBIT per Share too high?
Genomtec's current EBIT per Share is zł-0.60. Based on the distribution chart, Genomtec ranks #263 out of 689 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Genomtec has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Genomtec's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genomtec ranks #263 out of 689 companies for EBIT per Share. This puts Genomtec in the upper half of its industry. The industry median EBIT per Share is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genomtec and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomtec's current EBIT per Share is zł-0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomtec stock overvalued right now?
Genomtec (WAR:GMT) has a current EBIT per Share of zł-0.60. The current EBIT per Share is zł-0.60. Genomtec's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genomtec (WAR:GMT), the current EBIT per Share is zł-0.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genomtec Business Description

Other Exchanges 4VI:Germany
Address ul. Stablowicka 147, PORT Building 2, Wroclaw, POL, 54-066
Genomtec SA is an technology company which works in the area of ?? molecular diagnostics. It is a manufacturer of mobile molecular analyzers. The device are designed to identify pathogens including viruses, bacteria, and fungi by amplifying and detecting specific DNA and RNA fragments.
30GF Score

Get the complete analysis for WAR:GMT

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł4.80
Price